0001209191-23-044002.txt : 20230801
0001209191-23-044002.hdr.sgml : 20230801
20230801164116
ACCESSION NUMBER: 0001209191-23-044002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230728
FILED AS OF DATE: 20230801
DATE AS OF CHANGE: 20230801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FAIRBAIRN EMILY
CENTRAL INDEX KEY: 0001682638
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39692
FILM NUMBER: 231132357
MAIL ADDRESS:
STREET 1: 10 ORINDA VIEW ROAD
CITY: ORINDA
STATE: CA
ZIP: 94563
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IN8BIO, INC.
CENTRAL INDEX KEY: 0001740279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 825462585
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: EMPIRE STATE BUILDING
STREET 2: 350 5TH AVENUE, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: (646) 600-6438
MAIL ADDRESS:
STREET 1: EMPIRE STATE BUILDING
STREET 2: 350 5TH AVENUE, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: Incysus Therapeutics, Inc.
DATE OF NAME CHANGE: 20180510
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-28
0
0001740279
IN8BIO, INC.
INAB
0001682638
FAIRBAIRN EMILY
C/O IN8BIO, INC.
350 5TH AVENUE, SUITE 5330
NEW YORK
NY
10118
1
0
0
0
0
Common Stock
2023-07-28
4
J
0
4111958
0.00
D
0
I
See footnote
Common Stock
91336
I
See footnote
Common Stock
27706
I
See footnote
These securities are held by Transcend Partners Opportunity Fund I LLC ("Transcend"). Effective July 28, 2023, Transcend appointed new managing members and adopted a policy pursuant to which voting and dispositive decisions with respect to the Issuer's securities require the approval of at least two of Transcend's managers, Grant Fairbairn, Nina Fairbairn and Scott Kintz. Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by two or more individuals, and a voting and dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity's securities. Based upon the foregoing analysis, neither an individual manager of Transcend nor the Reporting Person exercises voting or dispositive control over any of the Issuer's securities, even those in which such person may hold a pecuniary interest.
The securities are held by Valley High Limited Partnership ("Valley High"). Emily Fairbairn's spouse is the sole managing partner of Valley High and has voting and investment power over the shares held by Valley High.
The securities are held by Emily T. Fairbairn Roth IRA ("Roth IRA"). Emily Fairbairn exercises control over the Roth IRA, and as such, has voting and investment power over the shares held by the Roth IRA.
/s/ Jason Minio, Attorney-in-Fact
2023-08-01